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Abstract
We have recently shown that green tea polyphenols, and especially (3)-epigallocatechin 3-gallate (EGCg), acted as potent
inhibitors of matrix metalloproteinase activities as well as of proMMP-2 activation (M. Demeule, M. Brossard, M. Page, D.
Gingras, R. Beliveau, Biochim. Biophys. Acta 1478 (2000)). In the present work, we sought to examine the involvement of
MT1-MMP in the EGCg-induced inhibition of proMMP-2 activation. The incubation of U-87 glioblastoma cells in the
presence of concanavalin A or cytochalasin D, two potent activators of MT1-MMP, resulted in proMMP-2 activation that
was correlated with the cell surface proteolytic processing of MT1-MMP to its inactive 43 kDa form. Addition of EGCg
strongly inhibited the MT1-MMP-dependent proMMP-2 activation. The inhibitory effect of EGCg on MT1-MMP was also
demonstrated by the down-regulation of MT1-MMP transcript levels and by the inhibition of MT1-MMP-driven cell
migration of transfected COS-7 cells. These observations suggest that this catechin may act at both the MT1-MMP gene and
protein expression levels. In addition, treatment of cells with non-cytotoxic doses of EGCg significantly reduced the amount
of secreted proMMP-2, and led to a concomitant increase in intracellular levels of that protein. This effect was similar to that
observed using well-characterized secretion inhibitors such as brefeldin A and manumycin, suggesting that EGCg could also
potentially act on intracellular secretory pathways. Taken together, these results indicate that EGCg targets multiple MMP-
mediated cellular events in cancer cells and provides a new mechanism for the anticancer properties of that molecule. ß 2002
Elsevier Science B.V. All rights reserved.
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1. Introduction
Green tea consumption has been associated in epi-
demiologic studies with decreased risk of various
proliferative diseases such as cancer and atheroscle-
rosis in humans [1,2]. These studies are based on the
observation that green tea possesses a number of
inhibitory activities against pathological or cell-dam-
aging processes such as carcinogenesis [3] and free
radical formation [4]. Its low toxicity, low cost, and
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natural abundance thus make it an attractive sub-
stance to investigate. Green tea consists mainly of
polyphenols (catechins) which constitute about 40%
of the dry weight of solids in brewed green tea, of
which (3)-epigallocatechin gallate (EGCg) is the
most abundant and the most extensively studied cat-
echin [5^7]. Numerous studies have suggested that
this catechin could in£uence tumor formation
through an inhibition of various cellular processes
involved in cell replication and DNA synthesis, by
interfering with cell-to-cell adhesion [8], or by inhib-
iting some of the intracellular communication path-
ways required for cell division [9,10]. The mecha-
nisms underlying the anticancer properties of EGCg
and green tea as a whole remain, however, largely
unknown.
The polyphenols present in green tea, particularly
EGCg, thus appear to a¡ect a number of molecular
processes that include induction of tumor cell apo-
ptosis and inhibition of tumor growth and invasion.
Since matrix metalloproteinases (MMPs) play an im-
portant role in these processes and have been linked
to tumor cell invasion [11,12], we thus examined
whether green tea catechins may further inhibit other
cellular MMP-mediated events in a highly metastatic
U-87 glioblastoma cell line. MMPs represent a grow-
ing family of zinc-dependent proteases involved in
matrix turnover occurring during normal and patho-
logical processes [12]. MMPs are secreted by cells as
proenzymes that must be cleaved in order to become
functional. This latency of the MMP zymogens is
due to the presence of the N-terminal pro-domain
that shields the catalytic cleft through coordination
of the catalytic zinc molecule [13]. Cleavage of the
pro-domains of MMPs is mediated in most cases by
soluble MMPs or by proteases of the serine families
such as plasmin, plasma kallikrein and neutrophil
elastase [12,14]. In contrast to most MMPs,
proMMP-2 possesses a propeptide that is not suscep-
tible to proteolytic cleavage by serine proteinases [15]
and recent evidence has suggested that its activation
is distinct and involves another member of the MMP
family, the membrane-type 1 MMP (MT1-MMP)
[16]. The intracellular molecular mechanisms in-
volved in MT1-MMP-dependent activation of
proMMP-2 at the cell surface is regulated by the
balance between MT1-MMP complexed by tissue in-
hibitor of matrix metalloproteinases (TIMP)-2 and
TIMP-2-free MT1-MMP [17] and results in MT1-
MMP proteolytic processing to its 43 kDa inactive
form [18^20]. The apparition of this inactive MT1-
MMP form was strongly correlated with MMP-2
activation [21]. However, the biological function
and regulation of this inactive MT1-MMP form re-
mains debated since it retains both its hemopexin
and cytoplasmic tail [19]. Such MT1-MMP proteo-
lytic mechanism was interestingly found to be oper-
ative in specialized plasma membrane domains such
as caveolae of U-87 glioma cells [22], and this local-
ization may prove important in the acquisition of
cancer cells’ invasive properties [23]. Whether any
of the MT1-MMP-mediated events is a¡ected by
green tea catechins is yet unknown.
We have recently reported that green tea polyphe-
nols, and particularly EGCg, potently inhibited
MMP activity both in vitro and in vivo [24], as
well as the activation of proMMP-2 in glioblastoma
cells and MT1-MMP-transfected COS-7 cells [22]. In
this report, we extended these results by showing that
green tea catechins, and especially EGCg, inhibited
proMMP-2 secretion from U-87 glioblastoma cells
and interfered with proMMP-2 activation through
a transcriptional regulation of the MT1-MMP gene.
Moreover, EGCg also speci¢cally antagonized MT1-
MMP-driven cell migration demonstrating a new po-
tential cellular target for this catechin.
2. Materials and methods
2.1. Materials
The human glioblastoma cell line U-87 was pur-
chased from the American Tissue Culture Collection
and maintained in modi¢ed Eagle’s medium (MEM)
containing 10% fetal bovine serum (HyClone Labo-
ratories), 100 units/ml penicillin, 100 Wg/ml strepto-
mycin. Concanavalin A (Con-A), cytochalasin D
(Cyto-D), brefeldin A, EGCg, (3)-epigallocatechin
(EGC), (3)-epicatechin (EC), (3)-epicatechin gallate
(ECg), manumycin, and nocodazole were purchased
from Sigma. The anti-MT1-MMP polyclonal anti-
body (raised against the hinge region) and monoclo-
nal antibody against human MMP-2 were from
Chemicon. The TriZOL reagent was from Gibco
and the Titan one-tube RT-PCR kit was from Roche
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Molecular Biochemicals. Reagents for electrophore-
sis were purchased from Bio-Rad.
2.2. Activation of proMMP-2 and isolation of
cell lysates
U-87 cells were plated in Nunc 33 mm six-well
plastic dishes at 105 cells/well and grown in a humidi-
¢ed atmosphere containing 5% CO2 and 90% air at
37‡C. The extent of proMMP-2 activity in the con-
ditioned medium and in cell lysates was evaluated by
the appearance of a 62 kDa gelatinolytic band on
gelatin zymograms following stimulation of the cells,
as described recently [21]. To induce activation, Con-
A (10 Wg/ml) or Cyto-D (1 WM) was added to the
conditioned medium and the cells were further incu-
bated in the presence or absence of the individual
catechins for di¡erent periods of time. No di¡erence
on U-87 cell adhesion was observed when cells were
either plated on plastic or gelatin-coated dishes in the
presence of the catechins (not shown). After removal
of the conditioned medium, cells were washed two
times in phosphate-bu¡ered saline and collected by
scraping. Crude membranes were isolated from U-87
cells in 20 mM Tris^HCl pH 7.4 following centrifu-
gation for 1 h at 200 000Ug at 4‡C. The resulting
particulate (membranes) and soluble (cytosol) frac-
tions were then examined by immunoblotting. For
the preparation of whole cell lysates, cells were re-
suspended in a bu¡er containing 1% Triton X-100,
0.5% Nonidet P-40, 150 mM NaCl and 20 mM Tris^
HCl pH 7.4. The mixture was incubated on ice for
1 h and insoluble matter was removed by centrifuga-
tion.
2.3. MMP-2 £uorimetric assays
Fluorimetric assays of the gelatinolytic activities of
MMP-2 were performed using the EnzChek Collage-
nase/Gelatinase kit as described previously [24].
Brie£y, 0.005^0.02 units (25^100 ng) of MMP-2
were mixed with 0.2 Wg/assay of quenched £uores-
cein-conjugated gelatin in a ¢nal volume of 100 Wl
of reaction bu¡er in 96-well microplates. The rate of
proteolysis, in the presence or absence of EGC,
EGCg or brefeldin A, was determined by measuring
the increase in £uorescence using a Fluoroskan II
Fluorimeter (Lab System), and was linear for at least
15 min under these conditions.
2.4. Immunoblotting procedures
Equal amounts of proteins from control and
treated cells were resuspended in sample bu¡er and
separated by SDS^PAGE, using 9% acrylamide gels.
After electrophoresis, proteins were electrotrans-
ferred to a 0.45 Wm pore size polyvinylidene di£uo-
ride (PVDF) membrane using a Milliblot graphite
electroblotter (Millipore) in the presence of a transfer
bu¡er containing 96 mM glycine, 10 mM Tris^HCl
and 10% methanol. Hydrophobic or non-speci¢c
sites were blocked overnight at 4‡C with 5% non-
fat dry milk in Tris-bu¡ered saline (150 mM Tris,
20 mM Tris^HCl, pH 7.5) containing 0.3% Tween
20 (TBST). Membranes were washed three times in
TBST and incubated with the primary antibodies
(1/1000 dilution) in TBST containing 3% bovine se-
rum albumin and 0.02% sodium azide, followed by a
1 h incubation at room temperature with horseradish
peroxidase-conjugated anti-rabbit IgG (1/10 000 dilu-
tion) or anti-mouse IgG (1/2500 dilution) in TBST
containing 5% non-fat dry milk. PVDF membranes
were washed three times in TBST and immunoreac-
tive material was visualized by enhanced chemilumi-
nescence (ECL, Amersham-Pharmacia Biotech).
2.5. RT-PCR analysis
U-87 cells were plated in Nunc 33 mm six-well
plastic dishes at 105 cells/well and were treated the
next day with Con-A (10 Wg/ml), or Cyto-D (1 WM),
in the presence or absence of 25 WM EGCg for 18 h
in serum-deprived medium. Then cell monolayers
were washed with PBS and total RNA was prepared
using TriZOL reagent following the manufacturer’s
instructions. One microgram of RNA was used for
¢rst-strand cDNA synthesis followed by speci¢c gene
product ampli¢cation using the Titan One Tube RT-
PCR Kit as described previously [22]. Primers were
all derived from human sequences; PCR conditions
were optimized so that the gene products were found
to be within the linear range for PCR ampli¢cation
[18]. PCR products were resolved on 2% (w/v) aga-
rose gels containing 1 Wg/ml ethidium bromide.
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2.6. Cell migration assay
To assess whether the di¡erent green tea polyphe-
nols a¡ected U-87 glioma cells migratory potential
and MT1-MMP-driven migration of COS-7 cells,
transwells (Costar; 8 Wm pore size) were precoated
with 0.5% gelatin/PBS by adding 200 Wl of the solu-
tion per transwell and allowing the membranes to air
dry in a laminar £ow hood at room temperature. The
transwells were then assembled in a 24-well plate
(Falcon 3097) and the lower chambers ¢lled with
600 Wl of MEM supplemented with 10% fetal bovine
serum. Cells were incubated for 2 h at 37‡C with the
particular catechin, spun down to remove the inhib-
itor from the medium, resuspended in 200 Wl fresh
MEM medium at 7.5U104 cells/ml, and inoculated
into the upper chamber of each transwell. The plate
was then placed at 37‡C in 5% CO2/95% air for 2 h.
Cells that had migrated to the lower surface of the
¢lters were ¢xed and stained with 0.1% crystal violet/
Fig. 1. Speci¢c transcriptional regulation of MT1-MMP-dependent activation of proMMP-2 in U-87 glioblastoma cells by EGCg.
(A) Control U-87 glioma cells were incubated in serum-deprived medium for 18 h to induce proMMP-2 secretion, and then treated
with 25 WM of the indicated catechins for another 18 h. 20 Wl of the conditioned medium were subjected to gelatin zymography.
(B) U-87 cells were treated as described in A with increasing EGCg concentrations in the presence or absence of 5 Wg/ml Con-A or 1
WM Cyto-D. Conditioned medium was saved to perform gelatin zymography, and cell lysates (20 Wg/well) were loaded on a 9% SDS-
gel to assess the level of the active 55 kDa and inactive 43 kDa MT1-MMP immunoreactive forms by Western blot. (C) Total RNA
was extracted from U-87 glioblastoma cells treated or not with 25 WM EGCg, 5 Wg/ml Con-A, or 1 WM Cyto-D for 18 h in serum-de-
prived medium. 1 Wg was subjected to RT-PCR analysis of MMP-2. The resulting ampli¢ed products of 222 bp for MMP-2, and 187
bp for MT1-MMP were resolved on 2% agarose gels containing 1 Wg/ml ethidium bromide.
BBAMCR 14836 5-2-02
B. Annabi et al. / Biochimica et Biophysica Acta 1542 (2002) 209^220212
20% MeOH, and counted. Data are presented as the
average number of migrated cells per ¢ve ¢elds
(U100).
3. Results
3.1. EGCg inhibits MT1-MMP-dependent
proMMP-2 activation through transcriptional
events in U-87 glioblastoma cells
We have previously shown that U-87 human glio-
blastoma cells constitutively secreted large amounts
of proMMP-2 into the conditioned medium and thus
represented a convenient model to study proMMP-2
activation [21]. We also showed that treatment of
these cells with Con-A or Cyto-D promoted a mas-
sive activation of proMMP-2 and that, among green
tea polyphenols, EGCg selectively inhibited this acti-
vation [24]. At that time, we hypothesized that this
catechin could inhibit proMMP-2 activation through
its interference with MT1-MMP activity.
In order to further assess the involvement of MT1-
MMP, we now examined the e¡ects of EGCg on
proMMP-2 activation induced by Con-A and Cyto-
D in highly invasive U-87 cells. As shown by gelatin
zymography in Fig. 1A, incubation of U-87 cells
with either Con-A or Cyto-D resulted in a marked
activation of proMMP-2 to its active form, and this
was speci¢cally antagonized by co-incubation of the
cells with EGCg but not with the other catechins
tested. Moreover, a dose-response incubation with
EGCg shows that MT1-MMP-dependent activation
of proMMP-2 by Con-A and Cyto-D was indeed
antagonized (Fig. 1B). This reduction in the activa-
tion of proMMP-2 correlated with a decrease in both
the active 55 kDa and inactive 43 kDa protein levels
of MT1-MMP suggesting that EGCg may act on
both the intracellular protein turnover of the protein
and at a transcriptional level. IC50 values for the in-
hibition of MT1-MMP protein turnover by EGCg
were calculated and derived from semi-log plots of
densitometric measurements of the 55 kDa form of
MT1-MMP (Fig. 1B), and were 3.2 þ 0.9 and
1.1 þ 0.8 WM respectively for the Con-A- and Cyto-
D-treated cells.
Total RNA was then isolated from control U-87
glioma cells or treated in the presence of EGCg. We
found that, while MMP-2 transcript levels were in-
creased in Con-A- and Cyto-D-treated cells (Fig.
Fig. 2. EGCg antagonizes MT1-MMP-induced cellular migration. Migration was assayed in a modi¢ed Boyden chamber as described
in Section 2. U-87 glioma or COS-7 cells were treated as described in the legend of Fig. 1 for 2 h. The cells were then trypsinized
and resuspended in MEM supplemented with serum. Cells (7.5U104 cells/ml) were inoculated into the upper chamber of each trans-
well. Migration was performed for 2 h at 37‡C, the number of cells that had migrated was determined by visually counting the cells
on the lower compartment of the ¢lter. The white bars represent no treatment, gray bars represent EGC treatment, and black bars
represent EGCg treatment. Data represent the mean of cells per microscope ¢eld of duplicate experiments.
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1C), they remained una¡ected in EGCg-treated U-87
cells. However, EGCg antagonized the increase of
either Con-A- or Cyto-D-induced MMP-2 gene ex-
pression. On the other hand, MT1-MMP transcript
levels were strikingly decreased in all EGCg-treated
cells (Fig. 1C). Since MT1-MMP is responsible for
the activation of proMMP-2 at the cell surface, these
results strongly suggest that EGCg may interfere
with the activity of this enzyme by regulating intra-
cellular MT1-MMP gene expression.
3.2. Speci¢c inhibitory e¡ect of EGCg on
MT1-MMP-induced cell migration
We have previously shown that recombinant MT1-
MMP expression induced COS-7 cell migration [22].
To further establish the involvement of MT1-MMP
in the inhibitory e¡ect of EGCg, we thus examined
the e¡ect of this catechin on the migratory potential
of these cells. A 2 h preincubation in the presence or
absence of the catechins EGC or EGCg was per-
formed, and migration of U-87 cells was compared
to COS-7 cells transfected or not with MT1-MMP
cDNA. As shown in Fig. 2, migration of U-87 cells
was speci¢cally inhibited by EGCg but not by EGC.
COS-7 cells, which lack endogenous MT1-MMP
[21,22], had their cell migration increased only
when they overexpressed MT1-MMP protein, and
this migration was also speci¢cally antagonized by
EGCg. This observation implies that EGCg may di-
rectly inhibit MT1-MMP activity that is crucial for
cell migration as it did not a¡ect the MT1-MMP
transcript levels in transiently MT1-MMP-trans-
fected COS-7 cells [22]. Direct demonstration for
such interaction could potentially be provided by
showing precipitation of EGCg using appropriate
MT1-MMP antibodies. MT1-MMP immunoprecipi-
tation was, however, unsuccessful in our conditions.
Finally, the rapid kinetic (2 h) of EGCg inhibition of
cell migration prompted us to further examine
Fig. 3. EGCg and brefeldin A inhibit proMMP-2 protein secretion in U-87 glioblastoma cells. Control U-87 glioblastoma cells were
cultured in serum-free medium and treated with 25 WM EGCg or 3 WM brefeldin A for 18 h. The conditioned medium was saved and
the cells subsequently washed in PBS 1U and lysed. The intracellular proMMP-2 protein pool was compared to the extracellular se-
creted proMMP-2 protein using Western blot analysis. Densitometric measurement was used to quantify the extent of proMMP-2 pro-
tein levels. White bars represent no treatment, black bars represent EGCg treatment, and gray bars represent brefeldin A treatment.
Data are the mean of three independent treatments.
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whether other intracellular MMP-mediated events
were also a¡ected.
3.3. EGCg rapidly inhibits proMMP-2 secretion from
U-87 glioblastoma cells
During the course of this study, we observed that
incubation of U-87 cells with EGCg signi¢cantly re-
duced the amount of proMMP-2 in the conditioned
medium despite no apparent e¡ects on cell viability
and MMP-2 transcript levels (Fig. 1C). We thus in-
vestigated whether that speci¢c catechin could a¡ect
the secretion of proMMP-2 from glioblastoma cells.
As shown in Fig. 3 (left panel), the addition of 25
WM EGCg to U-87 cells indeed resulted in a marked
reduction of proMMP-2 protein levels in the condi-
tioned medium (V50%), whereas intracellular
proMMP-2 levels concomitantly increased in the cor-
responding treated cell lysates. We next compared
the e¡ect of EGCg with that of brefeldin A, a well-
characterized compound that speci¢cally blocks
translocation of proteins from the endoplasmic retic-
ulum to the Golgi apparatus of the cell [25]. As
shown in Fig. 3 (right panel), incubation of the cells
in the presence of brefeldin A resulted in an accumu-
lation of proMMP-2 in the cell lysates and in a
marked reduction in the corresponding conditioned
medium. Moreover, whether proMMP-2 secretion
from U-87 cells was measured in the presence of
EGCg added at the beginning or after 24 h of serum
starvation, the catechin inhibitory e¡ect was seen ex-
tremely rapidly (less than 2 h after the addition of
EGCg) and resulted in an immediate buildup of an
intracellular proMMP-2 protein pool (Fig. 4). This
suggests that EGCg could reduce proMMP-2 secre-
tion very e⁄ciently and rapidly through a mechanism
a¡ecting some vesicular tra⁄cking pathway from the
intracellular MMP-2 pool to the plasma membrane
of U-87 cells. Moreover, such e¡ect could not be
attributed to a potential binding of MMP-2 at the
cell surface as intracellular MMP-2 buildup, induced
Fig. 4. Time-dependent inhibition of proMMP-2 secretion by
EGCg correlates with intracellular proMMP-2 sequestration. U-
87 glioblastoma cells were serum-starved for 48 h, and
proMMP-2 protein secretion and intracellular levels were moni-
tored by Western blot analysis and densitometric measurement.
(A) 20 Wl of the conditioned medium were saved at di¡erent
times and monitored for proMMP-2 protein secretion (a). 25
WM EGCg was added either at the beginning (E) or after 24 h
of serum deprivation (b). (B) 20 Wg of the corresponding con-
trol (open bars) or EGCg-treated (closed bar) U-87 cell lysates
were also isolated and blotted for proMMP-2 protein.
Fig. 5. EGCg-induced proMMP-2 intracellular accumulation is
not due to binding at the cell surface membrane of U-87 glio-
blastoma cells. U-87 glioma cells were serum-deprived and incu-
bated for 24 h in the presence of 25 WM EGC, 25 WM EGCg,
or 3 WM brefeldin A. Conditioned medium was saved and sub-
cellular fractionation was performed as described in Section 2
to isolate both the cytosol and a crude total membrane prepa-
ration. ProMMP-2 protein levels were examined by Western
blot in the respective fractions.
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through either brefeldin A or EGCg treatment of the
cells, was speci¢cally observed within the cytosolic
fraction and was not associated with cell-derived
membranes (Fig. 5). Other compounds known to
antagonize intracellular vesicular tra⁄cking such as
nocodazole [26], or to suppress MMP secretion such
as manumycin A [27] and U0126 [28] also decreased
the proMMP-2 protein levels secreted in the extra-
cellular media (not shown). This further de¢nes the
potential mechanistic e¡ect that EGCg may exert on
intracellular vesicular tra⁄cking in U-87 glioma
cells.
3.4. EGCg has a dual inhibitory enzymatic and
secretory e¡ect on MMP-2 in U-87 glioblastoma
cells
EGCg was demonstrated to inhibit MMP-2 gela-
tinolytic activity and to a greater extent MMP-12
activity [24]. The question as to whether the extracel-
Fig. 6. EGCg, but not brefeldin A, has a dual e¡ect on proMMP-2 gelatinolytic activity and protein secretion. U-87 glioblastoma cells
were serum-starved and treated with increasing concentrations of brefeldin A or EGCg. (A) The proMMP-2 gelatinolytic activity was
assessed by gelatin zymography using the corresponding conditioned medium (20 Wl) and cell lysates (20 Wg) after 18 h of treatment.
The extent of gelatin hydrolysis was quanti¢ed by densitometry and expressed as the percentage of the respective control. (B) Re-
combinant MMP-2 gelatinolytic activity was assayed using a £uorescent gelatin substrate in the presence of increasing concentrations
of brefeldin A, EGC, or EGCg (n = 3).
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lular and intracellular proMMP-2 protein levels re-
tained any enzymatic activity was thus assessed by
gelatin zymography. Here we show that EGCg and
brefeldin A antagonized proMMP-2 secretion in a
dose-responsive manner as assayed by gelatin zymog-
raphy (Fig. 6A), and that this resulted in a corre-
sponding increase in intracellular proMMP-2 gelatin-
olytic activity in the cell lysate. Interestingly, while
EGCg, but not EGC or brefeldin A, inhibited MMP-
2 in vitro activity (Fig. 6B), it did not seem to a¡ect
signi¢cantly the activity of the intracellular
proMMP-2 protein pool that had accumulated
(Fig. 6A). This further demonstrates the dual action
that EGCg exerts with regard to modulating both the
intracellular MMP-2 secretory pathway and the cat-
alytic activity of the MMP-2 enzyme.
4. Discussion
Activation of proMMP-2 by MT1-MMP located
at the tumor cell surface is thought to represent a
crucial step in tumor invasion and metastasis [11].
In gliomas, particularly, both MT1-MMP and the
activation of proMMP-2 have been strongly corre-
lated with glioma invasiveness [29,30]. These consid-
erations led us to investigate the molecular events
leading to proMMP-2 activation in glioma cells as
well as the involvement of the MT1-MMP protein in
this process. In addition, we report potential new
intracellular mechanistic targets of EGCg, a green
tea catechin, in MMP-mediated events that may
prove crucial with regard to its reported antimeta-
static e¡ect.
The ¢rst new target of EGCg that we report in this
study involves MT1-MMP per se and MT1-MMP-
mediated events in glioblastoma cells. It is now well
established that MT1-MMP enables and regulates
cell invasion activity [23,31,32]. Accordingly, overex-
pression of MT1-, MT2-, and MT3-MMP in epithe-
lial cells promoted invasion of basement membrane
whereas a wide range of soluble MMPs did not [23].
In agreement with these observations, we are now
showing that overexpression of recombinant MT1-
MMP in COS-7 cells indeed increased cell migration
through a gelatin matrix ([22]; this study). This
MT1-MMP-driven migration is also antagonized by
EGCg, which suggests a potential direct interaction
of this catechin with the overexpressed MT1-MMP
protein. Such hypothesis was indeed recently raised
by Garbisa et al. [33], who, however, did not char-
acterize the nature of the MT1-MMP (55 kDa active
vs. 43 kDa inactive) form a¡ected by EGCg. This
inhibition of cellular migration was similarly ob-
served in U-87 glioma cells and seemed speci¢c to
EGCg, since other catechins tested had little or no
e¡ect. Whether this e¡ect was cell speci¢c remains to
be investigated as ECg, in addition to EGCg, was
reported to suppress invasion of human HT-1080
¢brosarcoma cells [33,34] and of mouse lung carci-
noma LL2 cells [35]. The inhibitory e¡ect of EGCg
observed on cellular migration thus suggests that, in
addition to its ability to form complexes with metal
ions such as zinc [36], this catechin may also bind
and interact with speci¢c intramolecular sites of pro-
teins and, in the present study, speci¢cally target
MT1-MMP. Moreover, supporting this notion is
the low IC50 value obtained for the EGCg e¡ect on
MT1-MMP that is comparable to the EGCg plasma
concentration (0.3 WM) measured in human after
consumption of tea [37]. Whether EGCg a¡ects other
membrane-type MMPs is currently under investiga-
tion.
Recent studies have provided evidence that the
mechanisms of the inhibitory actions of EGCg may
involve, among other pathways, the inhibition of
phospho-ERK and phospho-c-jun formation. These
intermediate pathways are involved in transforma-
tion, di¡erentiation, and cell proliferation but,
more importantly, EGCg also inhibited activator
protein 1 (AP-1) function which has been associated
with invasive and metastatic characteristics of cancer
cells [38]. Interestingly, one class of genes that AP-1
regulates is MMPs, and increased MMP secretion
has been associated with AP-1 activity in the MCF-
7 breast cancer cell line [39]. This suggests that
EGCg may have access to and interact with extracel-
lular and intracellular proteins potentially involved
in signal transduction pathways. Recent studies
have indeed shown that [3H]EGCg was able to in-
corporate into the cytosol, as well as in the nuclei
[40]. Here, we show that EGCg speci¢cally down-
regulated MT1-MMP gene expression in glioma
cells, but not that of MMP-2, indicating that speci¢c
regulatory mechanisms underlying transcriptional
regulation of MT1-MMP may impair the initiation
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of the invasive phenotype of these cells. Intriguingly,
although most MMP genes are known to be strongly
regulated by AP-1 and AP-2 [38,41], the consensus
binding sites for these two transcription factors are
absent within the MT1-MMP promoter region [42]
and only AP-2 binding sites were found in the MMP-
2 promoter region [43]. This implies that some
unique MT1-MMP transcriptional control elements,
which remain to be identi¢ed, exist and are involved
in the EGCg inhibitory e¡ect. Interestingly and
although still debated, recent evidence has linked
Egr-1, a key transcription factor, to the initiation
of a migratory and invasive phenotype in tumor cells
[44,45]. It is thus tempting to suggest this candidate
transcription factor, whose consensus sites were ab-
sent from the TIMP-2 [46] and MMP-2 [47] pro-
moter regions, as possibly involved in the EGCg in-
hibitory e¡ect of both the MT1-MMP-dependent
activation of proMMP-2 and MT1-MMP-driven mi-
gration in glioma cells. Supporting this hypothesis is
the recently reported observation that, in EGCg-
treated vascular smooth muscle cells, Egr-1 mRNA
expression was strikingly reduced [10].
The second new and important intracellular e¡ect
that we observed in EGCg-treated glioma cells is the
inhibition of proMMP-2 protein secretion. This ob-
servation proved to be crucial as this e¡ect was not
observed in non-metastatic cell lines. EGCg seemed
to perturb the general intracellular vesicular tra⁄ck-
ing and, thus, the secretion of other soluble proteins
such as TIMP-2 (not shown). As the activation of
proMMP-2 at the cell surface is regulated by the
balance between MT1-MMP complexed by TIMP-2
and TIMP-2-free MT1-MMP, very low concentra-
tions of TIMP-2 should eventually prevent the for-
mation of the tri-molecular complex between
proMMP-2/TIMP-2/MT1-MMP that would lead to
MMP-2 activation and MT1-MMP autocatalytic
processing to its inactive form. Such regulation of
MT1-MMP proteolytic processing was shown to be
speci¢cally inhibited by TIMP-2 but not by TIMP-1,
and was also recently investigated by us [50^52].
Whether EGCg acts by limiting the extracellular lev-
els of TIMP-2 or surface binding to MT1-MMP is
presently not known, but certainly deserves further
investigation. We also demonstrated that EGCg
acted through a brefeldin A-like mechanism and
thus potentially blocked protein translocation from
endoplasmic reticulum to the Golgi apparatus [25],
as a concomitant increase in intracellular proMMP-2
protein levels was also observed. Interestingly,
EGCg’s e¡ect on proMMP-2 secretion was compa-
rable to that of manumycin A, a potent inhibitor of
Ras farnesyltransferase. Ras signaling was indeed re-
cently shown to play a critical role in the activation
of MMP-2 secretion [27,28]. Whether some of the
EGCg actions are mediated through the Ras path-
way remains speculative. Taken together, all these
observations thus emphasize the pleiotropic activity
of EGCg on intracellular MMP-mediated events and
may provide new insights into the mechanisms of
action of EGCg and green tea extract as cancer-pre-
ventive agents in humans.
During the last decade, green tea made from the
leaves of the plant Camellia sinensis has received con-
siderable attention as a preventing agent against can-
cer [7,48,49]. However, although the inhibition of
soluble extracellular MMPs by tea catechins and re-
lated polyphenols has been reported [24,33,35], few
studies have investigated the intracellular molecular
events involved in MMP secretion into the extracel-
lular media and those involved in activation process-
es of the MMP zymogens. In this report, we present
evidence that green tea catechins, and particularly
EGCg, target multiple new intracellular functions in-
volved in the activation and secretion of proMMP-2
from a highly invasive tumor cell line. Whether this
mechanism can be generalized to other protease sys-
tems deserves further investigation. Moreover, we
also provide support to a central role of MT1-
MMP as being responsible in the acquisition of the
invasive properties of cancer cells and that may also
represent a direct target of green tea in chemopre-
vention of cancer. Taken together, with numerous
recent reports on the inhibitory e¡ects of these mol-
ecules on various aspects of cancer cell biology, our
results emphasize the pleiotropic anticancer proper-
ties of green tea constituents. The clinical usefulness
of these molecules either as chemopreventive agents
or for the design of structural analogues thus repre-
sents an interesting area for future research.
Acknowledgements
We thank Dr. Michel Demeule for critical reading
BBAMCR 14836 5-2-02
B. Annabi et al. / Biochimica et Biophysica Acta 1542 (2002) 209^220218
of this manuscript. This work was supported by
grants from the Fondation Charles-Bruneau and
from the Socie¤te¤ de Recherche sur le Cancer du Can-
ada. B.A. was the recipient of a postdoctoral fellow-
ship from the Medical Research Council of Canada.
References
[1] C.J. Dufresne, E.R. Farnworth, A review of latest research
¢ndings on the health promotion properties of tea, J. Nutr.
Biochem. 12 (2001) 404^421.
[2] R.A. Riemersma, C.A. Rice-Evans, R.M. Tyrrell, M.N. Clif-
ford, M.E. Lean, Tea £avonoids and cardiovascular health,
QJM Mon. J. Assoc. Phys. 94 (2001) 277^282.
[3] C.S. Yang, J.M. Landau, M.T. Huang, H.L. Newmark, In-
hibition of carcinogenesis by dietary polyphenolic com-
pounds, Annu. Rev. Nutr. 21 (2001) 381^406.
[4] W. Bors, M. Saran, Radical scavenging by £avonoid antioxi-
dants, Free Radic. Res. Commun. 2 (1987) 289^294.
[5] C.S. Yang, Z.Y. Wang, Tea and cancer, J. Natl. Cancer Inst.
85 (1993) 1038^1049.
[6] D.A. Balentine, S.A. Wiseman, L.C. Bouwens, The chemis-
try of tea £avonoids, Crit. Rev. Food Sci. Nutr. 37 (1997)
693^704.
[7] H. Mukhtar, N. Ahmad, Green tea in chemoprevention of
cancer, Toxicol. Sci. 52 (1999) 111^117.
[8] M. Isemura, Y. Suzuki, K. Satoh, K. Narumi, M. Moto-
miya, E¡ects of catechins on the mouse lung carcinoma
cell adhesion to the endothelial cells, Cell Biol. Int. 17
(1993) 559^564.
[9] J.Y. Chung, C. Huang, X. Meng, Z. Dong, C.S. Yang, In-
hibition of activator protein 1 activity and cell growth by
puri¢ed green tea and black tea polyphenols in H-ras-trans-
formed cells : structure-activity relationship and mechanisms
involved, Cancer Res. 59 (1999) 4610^4617.
[10] H.Y. Ahn, K.R. Hadizadeh, C. Seul, Y.P. Yun, H. Vetter,
A. Sachinidis, Epigallocathechin-3 gallate selectively inhibits
the PDGF-BB-induced intracellular signaling transduction
pathway in vascular smooth muscle cells and inhibits trans-
formation of sis-transfected NIH 3T3 ¢broblasts and human
glioblastoma cells (A172), Mol. Biol. Cell 10 (1999) 1093^
1104.
[11] M. Polette, P. Birembaut, Membrane-type metalloprotei-
nases in tumor invasion, Int. J. Biochem. Cell Biol. 30
(1998) 1195^1202.
[12] M.A. Forget, R.R. Desrosiers, R. Be¤liveau, Physiological
roles of matrix metalloproteinases: implications for tumor
growth and metastasis, Can. J. Physiol. Pharmacol. 77
(1999) 465^480.
[13] E. Morgunova, A. Tuuttila, U. Bergmann, M. Isupov, Y.
Lindqvist, G. Schneider, K. Tryggvason, Structure of human
pro-matrix metalloproteinase-2: activation mechanism re-
vealed, Science 284 (1999) 1667^1670.
[14] H. Nagase, Activation mechanisms of matrix metalloprotei-
nases, Biol. Chem. 378 (1997) 151^160.
[15] Y. Okada, T. Morodomi, J.J. Enghild, K. Suzuki, A. Yasui,
I. Nakanishi, G. Salvesen, H. Nagase, Matrix metalloprotei-
nase 2 from human rheumatoid synovial ¢broblasts. Puri¢-
cation and activation of the precursor and enzymic proper-
ties, Eur. J. Biochem. 194 (1990) 721^730.
[16] H. Sato, T. Takino, Y. Okada, J. Cao, A. Shinagawa, E.
Yamamoto, M. Seiki, A matrix metalloproteinase expressed
on the surface of invasive tumour cells, Nature 370 (1994)
61^65.
[17] E. Maquoi, F. Frankenne, E. Baramova, C. Munaut, N.E.
Sounni, A. Remacle, A. Noel, G. Murphy, J.M. Foidart,
Membrane type 1 matrix metalloproteinase-associated deg-
radation of tissue inhibitor of metalloproteinase 2 in human
tumor cell lines, J. Biol. Chem. 275 (2000) 11368^11378.
[18] M. Ailenberg, M. Silverman, Cellular activation of mesan-
gial gelatinase A by cytochalasin D is accompanied by en-
hanced mRNA expression of both gelatinase A and its mem-
brane-associated gelatinase A activator (MT-MMP),
Biochem. J. 313 (1996) 879^884.
[19] K. Lehti, J. Lohi, H. Valtanen, J. Keski-Oja, Proteolytic
processing of membrane-type-1 matrix metalloproteinase is
associated with gelatinase A activation at the cell surface,
Biochem. J. 334 (1998) 345^353.
[20] M. Yu, H. Sato, M. Seiki, S. Spiegel, E.W. Thompson, Ele-
vated cyclic AMP suppresses ConA-induced MT1-MMP ex-
pression in MDA-MB-231 human breast cancer cells, Clin.
Exp. Metastasis 16 (1998) 185^191.
[21] D. Gingras, M. Page¤, B. Annabi, R. Be¤liveau, Rapid activa-
tion of matrix metalloproteinase-2 by glioma cells occurs
through a posttranslational MT1-MMP-dependent mecha-
nism, Biochim. Biophys. Acta 1497 (2000) 341^350.
[22] B. Annabi, M.P. Lachambre, N. Bousquet-Gagnon, M.
Page¤, D. Gingras, R. Be¤liveau, Localization of membrane-
type 1 matrix metalloproteinase in caveolae membrane do-
mains, Biochem. J. 353 (2001) 547^553.
[23] H. Hotary, E. Allen, A. Punturieri, I. Yana, S.J. Weiss,
Regulation of cell invasion and morphogenesis in a three-
dimensional type I collagen matrix by membrane-type matrix
metalloproteinases 1, 2, and 3, J. Cell Biol. 149 (2000) 1309^
1323.
[24] M. Demeule, M. Brossard, M. Page, D. Gingras, R. Beli-
veau, Matrix metalloproteinase inhibition by green tea cat-
echins, Biochim. Biophys. Acta 1478 (2000) 51^60.
[25] C.L. Jackson, Brefeldin A revealing the fundamental princi-
ples governing membrane dynamics and protein transport,
Subcell. Biochem. 34 (2000) 233^272.
[26] D.F. Alonso, H.G. Farina, C. Arregui, M.A. Aon, D.E.
Gomez, Modulation of urokinase-type plasminogen activa-
tor and metalloproteinase activities in cultured mouse mam-
mary-carcinoma cells : enhancement by paclitaxel and inhi-
bition by nocodazole, Int. J. Cancer 83 (1999) 242^246.
[27] A.A. Thant, T.T. Sein, E. Liu, K. Machida, F. Kikkawa, T.
Koike, M. Seiki, S. Matsuda, M. Hamaguchi, Ras pathway
is required for the activation of MMP-2 secretion and for the
BBAMCR 14836 5-2-02
B. Annabi et al. / Biochimica et Biophysica Acta 1542 (2002) 209^220 219
invasion of src-transformed 3Y1, Oncogene 18 (1999) 6555^
6563.
[28] E. Liu, A.A. Thant, F. Kikkawa, H. Kurata, S. Tanaka, A.
Nawa, S. Mizutani, S. Matsuda, H. Hanafusa, M. Hamagu-
chi, The Ras-mitogen-activated protein kinase pathway is
critical for the activation of matrix metalloproteinase secre-
tion and the invasiveness in v-crk-transformed 3Y1, Cancer
Res. 60 (2000) 2361^2364.
[29] P.A. Forsyth, H. Wong, T.D. Laing, N.B. Rewcastle, D.G.
Morris, H. Muzik, K.J. Leco, R.N. Johnston, P.M. Brasher,
G. Sutherland, D.R. Edwards, Gelatinase-A (MMP-2), ge-
latinase-B (MMP-9) and membrane type matrix metallopro-
teinase-1 (MT1-MMP) are involved in di¡erent aspects of
the pathophysiology of malignant gliomas, Br. J. Cancer
79 (1999) 1828^1835.
[30] A.T. Belien, P.A. Paganetti, M.E. Schwab, Membrane-type 1
matrix metalloprotease (MT1-MMP) enables invasive migra-
tion of glioma cells in central nervous system white matter,
J. Cell Biol. 144 (1999) 373^384.
[31] H. Nakahara, L. Howard, E.W. Thompson, H. Sato, M.
Seiki, Y. Yeh, W.T. Chen, Transmembrane/cytoplasmic do-
main-mediated membrane type 1-matrix metalloprotease
docking to invadopodia is required for cell invasion, Proc.
Natl. Acad. Sci. USA 94 (1997) 7959^7964.
[32] K. Lehti, H. Valtanen, S. Wickstrom, J. Lohi, J. Keski-Oja,
Regulation of membrane-type-1 matrix metalloproteinase
activity by its cytoplasmic domain, J. Biol. Chem. 275
(2000) 15006^15013.
[33] S. Garbisa, L. Sartor, S. Biggin, B. Salvato, R. Benelli, A.
Albini, Tumor gelatinases and invasion inhibited by the
green tea £avonol epigallocatechin-3-gallate, Cancer 91
(2001) 822^832.
[34] M. Maeda-Yamamoto, H. Kawahara, N. Tahara, K. Tsuji,
Y. Hara, M. Isemura, E¡ects of tea polyphenols on the
invasion and matrix metalloproteinases activities of human
¢brosarcoma HT1080 cells, J. Agric. Food Chem. 47 (1999)
2350^2354.
[35] M. Isemura, K. Saeki, T. Minami, S. Hayakawa, T. Kimura,
Y. Shoji, M. Sazuka, Inhibition of matrix metalloproteinases
by tea catechins and related polyphenols, Ann. NY Acad.
Sci. 878 (1999) 629^631.
[36] I.R. Record, J.K. McInerney, I.E. Dreosti, Black tea, green
tea, and tea polyphenols. E¡ects on trace element status in
weanling rats, Biol. Trace Elem. Res. 53 (1996) 27^43.
[37] Y. Cao, R. Cao, Angiogenesis inhibited by drinking tea,
Nature 398 (1999) 381.
[38] H.C. Crawford, L.M. Matrisian, Mechanisms controlling the
transcription of matrix metalloproteinase genes in normal
and neoplastic cells, Enzyme Protein 49 (1996) 20^37.
[39] J.A. Dumont, A.J. Bitonti, C.D. Wallace, R.J. Baumann,
E.A. Cashman, D.E. Cross-Doersen, Progression of MCF-
7 breast cancer cells to antiestrogen-resistant phenotype is
accompanied by elevated levels of AP-1 DNA-binding activ-
ity, Cell Growth Di¡er. 7 (1996) 351^359.
[40] S. Okabe, M. Suganuma, M. Hayashi, E. Sueoka, A. Ko-
mori, H. Fujiki, Mechanisms of growth inhibition of human
lung cancer cell line, PC-9, by tea polyphenols, Jpn. J. Can-
cer Res. 88 (1997) 639^643.
[41] M.P. Vincenti, L.A. White, D.J. Schroen, U. Benbow, C.E.
Brinckerho¡, Regulating expression of the gene for matrix
metalloproteinase-1 (collagenase): mechanisms that control
enzyme activity, transcription, and mRNA stability, Crit.
Rev. Eukaryotic Gene Expr. 6 (1996) 391^411.
[42] T.L. Haas, D. Stitelman, S.J. Davis, S.S. Apte, J.A. Madri,
Egr-1 mediates extracellular matrix-driven transcription of
membrane type 1 matrix metalloproteinase in endothelium,
J. Biol. Chem. 274 (1999) 22679^22685.
[43] H. Qin, Y. Sun, E.N. Benveniste, The transcription factors
Sp1, Sp3, and AP-2 are required for constitutive matrix met-
alloproteinase-2 gene expression in astroglioma cells, J. Biol.
Chem. 274 (1999) 29130^29137.
[44] M.A. Eid, M.V. Kumar, K.A. Iczkowski, D.G. Bostwick,
D.J. Tindall, Expression of early growth response genes in
human prostate cancer, Cancer Res. 58 (1998) 2461^2468.
[45] C. Liu, E. Adamson, D. Mercola, Transcription factor
EGR-1 suppresses the growth and transformation of human
HT-1080 ¢brosarcoma cells by induction of transforming
growth factor beta 1, Proc. Natl. Acad. Sci. USA 93
(1996) 11831^11836.
[46] Y.A. De Clerck, M.I. Darville, Y. Eeckhout, G.G. Rous-
seau, Characterization of the promoter of the gene encoding
human tissue inhibitor of metalloproteinases-2 (TIMP-2),
Gene 139 (1994) 185^191.
[47] P.R. Mertens, S. Harendza, A.S. Pollock, D.H. Lovett, Glo-
merular mesangial cell-speci¢c transactivation of matrix met-
alloproteinase 2 transcription is mediated by YB-1, J. Biol.
Chem. 272 (1997) 22905^22912.
[48] B.D. Lyn-Cook, T. Rogers, Y. Yan, E.B. Blann, F.F. Kad-
lubar, G.J. Hammons, Chemopreventive e¡ects of tea ex-
tracts and various components on human pancreatic and
prostate tumor cells in vitro, Nutr. Cancer 35 (1999) 80^
86.
[49] Y. Kuroda, Y. Hara, Antimutagenic and anticarcinogenic
activity of tea polyphenols, Mutat. Res. 436 (1999) 69^97.
[50] H. Stanton, J. Gavrilovic, S.J. Atkinson, M.P. d’Ortho,
K.M. Yamada, L. Zardi, G. Murphy, The activation of
proMMP-2 (gelatinase A) by HT-1080 ¢brosarcoma cells is
promoted by culture on a ¢bronectin substrate and is con-
comitant with an increase in processing of MT1-MMP
(MMP-14) to a 45 kDa form, J. Cell Sci. 111 (1998) 2789^
2798.
[51] S. Hernandez-Barrantes, M. Toth, M.M. Bernardo, M. Yur-
kova, D.C. Gervasi, Y. Raz, Q.A. Sang, R. Fridman, Bind-
ing of active (57 kDa) membrane type 1-matrix metallopro-
teinase (MT1-MMP) to tissue inhibitor of metalloproteinase
(TIMP)-2 regulates MT1-MMP processing and pro-MMP-2
activation, J. Biol. Chem. 275 (2000) 12080^12089.
[52] B. Annabi, A. Pilorget, N. Bousquet-Gagnon, D. Gingras,
R. Be¤liveau, Calmodulin inhibitors trigger the proteolytic
processing of membrane-type 1 matrix metalloproteinase
but not its shedding in glioma cells, Biochem. J. 359 (2001)
325^333.
BBAMCR 14836 5-2-02
B. Annabi et al. / Biochimica et Biophysica Acta 1542 (2002) 209^220220
